Final Program [International AIDS Society (11th: 1996: Vancouver, Canada)]

-g - 6.0 *
VENUE ROOM TRACK SESSION NO. TIME / SESSION PATHWAYS
I I t
S B2 337 Track B: Clinical Science
Hall B Abstract Session:
North Mycobacterium avium Complex (MAC)
Chairs:
Gerald Friedland, USA / Anita Rachlis, Canada...............................................................................................................................................................................................................................................
We.B.420 15:30
MYCOBACTERIUM AVIUM COMPLEX IN CHILDREN WITH AIDS, UNITED STATES: NEED FOR SPECIFIC PROPHYLAXIS
GUIDELINES FOR CHILDREN LESS THAN 6 YEARS OLD
Lindegren MLI, Hanson C2, Saletan S3, Beil J4, Posid, Josephi,Valappil TI, Fleming Pl,Ward ji. ICDC, Atlanta, GA; 2Baylor College of
Medicine, Houston,TX; 3NYC Dept. of Health, New York, NY; 4New Jersey Dept. of Health,Trenton, NJ, USA................................................................................................................................................................................................................................................
We.B.421 15:45
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF
CLARITHROMYCIN VS RIFABUTIN VS THE COMBINATION FOR THE PREVENTION OF MYCOBACTERIUM AVIUM COMPLEX
BACTEREMIA OR DISSEMINATED MAC DISEASE IN HIV-INFECTED PATIENTS WITH CD4 COUNTS <100 CELLS/mm3
Cohn, David L, Benson CA,Williams P Nevin T Korvick J, Hafner R, Bourland D, Kopek E, Becker S, Hojczyk RTimmons P Child C,
ACTG 196/CPCRA 009 Protocol Team. AIDS Clinical Trials Group (ACTG) & Terry Biern Community Programs for Clinical Research
on AIDS (CPCRA), USA................................................................................................................................................................................................................................................
We.B.422 16:00
THE FRENCH RAMDOMIZED CLINICAL TRIAL OF COMBINATION THERAPY WITH CLARITHROMYCIN FOR MAC
BACTEREMIA IN AIDS PATIENTS: FINAL RESULTS
MayTI,VincentV2, Brel, F Beuscart C, Perronne C, Doco-Lecompte T Dautzenberg B, Grosset ji and CURAVIUM Group................................................................................................................................................................................................................................................
We.B.423 16:15
RIFABUTIN, ETHAMBUTOL AND CLARITHROMYCIN IS SUPERIOR TO RIFAMPIN, ETHAMBUTOL, CLOFAZIMINE AND
CIPROFLOXACIN FOR MAC BACTEREMIA (CTN 010)
Shafran, Stephen D, Singer J, Zarowny DR Phillips P Salit I, Walmsley S, Fong I, Gill J. University of Alberta and the Canadian HIV Trials
Network Protocol 010 Study Group, Canada.
M...............................................................................................................................................................................................................................................
S We.B.424 16:30
b NATURAL COURSE OF MAC INFECTION IN 101 PATIENTS WITH HIV-I INFECTION AND CD4 COUNTS BELOW
D 100/mL IN RELATION TO CD4 COUNTS AND SYMPTOMS
0
C Bogner Johannes R, Rusch-Gerdes S, MertenskotterT, Loch O, Emminger C, Baumgarten R, Stoehr A, Albrecht H, Jablonowski H,
> Dietrich M for the German AIDS Study Group (GASG/IdkF), Robert Koch Institut/BMG, Munich, Germany................................................................................................................................................................................................................................................
16:45
c STATE OF THE ART MAC PROPHYLAXIS AND THERAPY
Chaisson, Richard. Johns Hopkins University School of Medicine, Baltimore, MD, USA.
o
U)
C
O
u
aa
a
X

208